亚甲氨基粉症:当代观点
Safak Mirioglu1,2, Omer Uludag3, Ozge Hurdogan4
1Division of Nephrology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey. smirioglu@gmail.com.
Current rheumatology reports
|April 3, 2024
概括
慢性炎症的并发症AA氨基粉症,由于更好的疾病治疗,正在下降. 目前的管理重点是减少血清粉样蛋白A蛋白,新的生物药物改善了结果,尽管粉样蛋白沉积物清除仍然是一个挑战.
科学领域:
- 类风湿病学 类风湿病学
- 腎臟病學 (nephrology) 是一種醫學專業.
- 心脏病学 心脏病学
背景情况:
- 粉样粉症是一种慢性炎症疾病的严重并发症.
- 它可以导致器官损伤和危及生命的结果.
- 最近的进展影响了其管理和预后.
研究的目的:
- 审查AA氨基粉症的流行病学.
- 讨论病因,病原和临床表现.
- 概述当前和新兴的诊断和治疗策略.
主要方法:
- 对AA氨基粉症的文献综述.
- 对流行病学趋势的分析.
- 评估诊断方式,包括组织病理学和MRI.
- 对治疗干预措施的评估.
主要成果:
- 由于对潜在的炎症性疾病的治疗得到改善,AA Amyloidosis的发生率有所降低.
- 组织病理学是诊断的黄金标准;MRI有助于检测心脏参与.
- 目前的治疗重点是降低血清粉样蛋白A蛋白,生物药物显著改善了管理.
- 移植是有效的,由于新的疗法,移植后的复发很少发生.
结论:
- 对AA氨基粉症的治疗已经随着新型抗炎疗法的发展而发展.
- 控制炎症是关键,但仍然需要用于粉样蛋白沉积物清除的药物.
- 对直接粉样蛋白清除疗法的进一步研究是有必要的.
相关概念视频
Amyloid Fibrils
9.5K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
9.5K
Alzheimer's Disease: Overview
469
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
469
Alzheimer's Disease: Treatment
184
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
184


